Harmony Biosciences (HRMY) to Release Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is scheduled to post its quarterly earnings results before the market opens on Tuesday, October 29th. Analysts expect Harmony Biosciences to post earnings of $0.66 per share for the quarter. Harmony Biosciences has set its FY 2024 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.24. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The company had revenue of $172.80 million for the quarter, compared to analyst estimates of $172.53 million. During the same period in the prior year, the business earned $0.56 earnings per share. Harmony Biosciences’s quarterly revenue was up 28.8% on a year-over-year basis. On average, analysts expect Harmony Biosciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Harmony Biosciences Price Performance

Shares of HRMY stock opened at $34.50 on Friday. Harmony Biosciences has a 1 year low of $19.03 and a 1 year high of $40.60. The firm’s 50 day moving average is $36.40 and its 200-day moving average is $32.96. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 17.69, a PEG ratio of 0.69 and a beta of 0.73. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on HRMY shares. Needham & Company LLC reissued a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research note on Wednesday, October 2nd. Mizuho boosted their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, October 10th. UBS Group started coverage on shares of Harmony Biosciences in a research note on Tuesday, September 10th. They set a “buy” rating and a $56.00 price target for the company. Finally, Raymond James reissued an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a research note on Thursday, October 10th. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.38.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.